These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12722405)

  • 1. [Comparison of quality of life in patients with advanced ovarian cancer treated with intraperitoneal or intravenous cisplatin and cyclophosphamide as a second line of therapy].
    Majdak E; Krasińska L; Mielcarek P; Kobierski J; Kozaka J; Milczek T; Emerich J
    Ginekol Pol; 2002 Nov; 73(11):1096-102. PubMed ID: 12722405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
    N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study of different chemotherapy approaches for advanced epithelial ovarian cancer].
    Chen YL; Liu YQ; Tang DH; Chu CN
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):110-4. PubMed ID: 18683749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palliative care opportunities for women with advanced ovarian cancer associated with intraperitoneal chemotherapy.
    Otis-Green S; Wakabayashi MT; Morgan R; Hakim A; Ferrell B; Sun V; Yang E; Grant M
    J Palliat Med; 2013 Jan; 16(1):44-53. PubMed ID: 23272673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
    Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
    Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
    J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 13. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient.
    Giger-Pabst U; Solass W; Buerkle B; Reymond MA; Tempfer CB
    Anticancer Res; 2015 Apr; 35(4):2309-14. PubMed ID: 25862894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Recio FO; Piver MS; Hempling RE; Driscoll DL
    Gynecol Oncol; 1998 Mar; 68(3):267-73. PubMed ID: 9570979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer.
    Burkett AM; Cohn DE; Copeland LJ
    Gynecol Oncol; 2007 Feb; 104(2):491-3. PubMed ID: 17150244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy.
    Nicoletto MO; Casarin A; Baldoni A; Rulli E; Tasca G; Baretta Z; Artioli G; Lombardi G; Cappetta A; Floriani I; Randon G; Valpione S; Litta P; Conte P; Mocellin S; Aliberti C
    Anticancer Res; 2016 Dec; 36(12):6541-6546. PubMed ID: 27919980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.